Invention Grant
- Patent Title: Human monoclonal antibodies to ganglioside GD2
-
Application No.: US14730036Application Date: 2015-06-03
-
Publication No.: US09856324B2Publication Date: 2018-01-02
- Inventor: Wolfgang Scholz , Ritsuko Sawada
- Applicant: MabVax Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: MabVax Therapeutics, Inc.
- Current Assignee: MabVax Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/30 ; A61K39/395 ; A61K45/06 ; G01N33/574

Abstract:
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
Public/Granted literature
- US20150353645A1 HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 Public/Granted day:2015-12-10
Information query